Department of Obstetrics and Gynecology, Faculty of Medicine Universitas Lambung Mangkurat, Ulin General Hospital, Banjarmasin, South Borneo, Indonesia
Auto-generated profile, based on publicly available information
Hariadi Yuseran
Department of Obstetrics and Gynecology, Faculty of Medicine Universitas Lambung Mangkurat, Ulin General Hospital, Banjarmasin, South Borneo, Indonesia
BACKGROUND Botryoid rhabdomyosarcoma is a subtype of embryonal rhabdomyosarcoma and is a rare and highly vascular malignant childhood tumor, with the most common sites of origin being the vagina and cervix in young girls. This report describes the case of a 15-year-old girl presenting with vaginal hemorrhage due to botryoid rhabdomyosarcoma treated with emergency radiation therapy. Hemorrhage in botryoid rhabdomyosarcoma can present as a life-threatening emergency requiring immediate intervention. This case highlights the role of emergency external radiation therapy as a valuable adjunct in managing hemorrhage in botryoid rhabdomyosarcoma, especially when surgical options are limited. CASE REPORT We report a case of a 15-year-old girl who experienced repeated profuse episodes of vaginal bleeding and protruding mass in the vagina for 2 months. She had no significant medical history or family history of cancer. Magnetic resonance imaging (MRI) confirmed a massive malignant mass in the vaginal introitus that infiltrated the cervix, extending to the uterus. Based on the histopathology result, the diagnosis was botryoid rhabdomyosarcoma with a primary site located on the cervix, and due to the emergency situation and the risks associated with surgical intervention, emergency external radiation therapy was initiated. After 1 session of radiation therapy, the bleeding was significantly reduced. CONCLUSIONS Hemorrhage in botryoid rhabdomyosarcoma is a rare but critical complication. Emergency external radiation therapy helps stabilize the patient with acute bleeding caused by botryoid rhabdomyosarcoma. Further research is needed to find the optimal treatment strategies.
HIGHLIGHTSABSTRACTObjective: The aim of this study was to investigate the characteristics of the Gynecology Oncology Outpatient Clinic at Ulin Hospital Banjarmasin before and after the COVID-19 pandemic. Materials and Methods: This descriptive study utilized existing patient data from the Gynecology Oncology Outpatient Clinic at Ulin Hospital Banjarmasin covering the period from March 2019 to February 2021. The study received ethical approval from the Ulin General Hospital ethics committee with clearance number 10/I-Reg Research/RSUDU/23. The collected data was presented in a tabular format to compare the service characteristics before the pandemic (March 2019 - February 2020) and after the pandemic (March 2020 – February 2021). Results: During the periods of March 2019 – February 2020 and March 2020 – February 2021, there was a reduction of 19% in patient visits. The number of patients undergoing treatment also decreased, from 1081 patients (53.9%) in the period of March 2019 – February 2020 to 926 patients (46.1%) in the period of March 2020 – February 2021. Notably, there was a decrease in the number of patients undergoing surgical procedures, dropping from 76 patients (70.4%) in the period of March 2019 – February 2020 to 32 patients (29.6%) in the period of March 2020 – February 2021. A similar trend was seen in patients receiving chemotherapy, with the count decreasing from 1005 patients (52.9%) in the period of March 2019 – February 2020 to 894 patients (47.1%) in the period of March 2020 – February 2021. These changes were attributed to various hospital measures implemented to address the COVID-19 pandemic, including a reduction in outpatient clinic visits and the temporary suspension of surgical procedures from March 2020 to October 2020 to minimize potential exposure. Conclusion: The study highlights a noticeable decline in both the frequency of visits to the Gynecology Oncology Outpatient Clinic at Ulin Regional General Hospital Banjarmasin and the number of patients receiving treatment during the periods before and after the onset of the COVID-19 pandemic.